Approach to the treatment-naïve patient with HCV genotype 1 infection.
In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients.
Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Room 0311 Terrace Level 2400 Pratt Street, Durham, NC 27715, USA. andrew.muir@duke.edu
Andrew J
AJ
Muir
D000465:Algorithms; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load / Q000187:drug effects
D000998:Antiviral Agents; D012367:RNA, Viral